Clinical Trials for Head And Neck Cancer

A Phase II Trial of Lovastatin and Pembrolizumab in Patients with RM HNSCC (LAPP)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma (ECOG 0–1) not candidates for salvage surgery receive pembrolizumab plus oral lovastatin; prior checkpoint inhibitor use and current statin therapy are excluded. Pembrolizumab is an anti–PD-1 antibody, and lovastatin (HMG‑CoA reductase inhibitor) is added to potentially enhance antitumor immunity via mevalonate pathway inhibition.

ClinicalTrials.gov ID: NCT06636734

Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent/metastatic nasopharyngeal carcinoma after platinum–gemcitabine and prior PD‑1/L1 therapy (up to two prior lines; ECOG 0–2; treated/stable brain mets allowed) are randomized to nivolumab (PD‑1) plus ipilimumab (CTLA‑4) with or without cabozantinib, a multikinase inhibitor of MET/VEGFR2/AXL. Aims to determine whether adding cabozantinib improves outcomes versus dual checkpoint blockade alone.

ClinicalTrials.gov ID: NCT05904080

Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with oligometastatic HNSCC (≤4 metastatic sites) who have not progressed after 3 cycles of pembrolizumab plus platinum/fluorouracil- or paclitaxel-based chemotherapy are randomized to maintenance pembrolizumab (PD-1 inhibitor) with consolidative radiotherapy to all disease sites versus pembrolizumab alone. Requires measurable disease, ECOG 0–1 at induction (0–2 at randomization), no prior head/neck RT, and no active autoimmune disease needing systemic therapy.

ClinicalTrials.gov ID: NCT05721755

Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent or metastatic nasopharyngeal carcinoma, systemic treatment–naïve for the metastatic setting and with measurable disease, receive induction gemcitabine/platinum plus toripalimab (anti–PD-1), with optional switch to carboplatin from cycle 2, followed by maintenance toripalimab. Excludes candidates for curative local therapy, prior systemic therapy for R/M disease, early recurrence after chemoradiation (<6 months), rapidly progressive disease, and active/untreated CNS metastases.

ClinicalTrials.gov ID: NCT06457503

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling children and adults with NTRK1/2/3 fusion–positive differentiated thyroid cancer (post-thyroidectomy) with CT-evaluable pulmonary metastases and no prior RAI or systemic therapy. Patients receive a 6-month lead-in of larotrectinib (selective TRKA/B/C inhibitor) followed by radioactive iodine (131I), aiming to enhance RAI avidity and induce complete pulmonary responses.

ClinicalTrials.gov ID: NCT05783323

Randomized Phase II Trial of Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with symptomatic or progressive radioactive iodine–resistant differentiated thyroid cancer (papillary/follicular/Hürthle; ECOG 0–2; ≤1 prior VEGF/VEGFR therapy) are randomized to lenvatinib monotherapy starting at 24 mg/day versus 10 mg/day. Lenvatinib is a multikinase inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT; the study tests whether a lower starting dose improves tolerability without compromising antitumor activity.

ClinicalTrials.gov ID: NCT07092514

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424

A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with treatment-naïve, recurrent/metastatic incurable HNSCC of the oral cavity/oropharynx (HPV/p16-negative required)/hypopharynx/larynx (ECOG 0–1, measurable disease; excludes nasopharynx/unknown primary), this study randomizes patients to pembrolizumab + carboplatin with or without amivantamab. Amivantamab is a bispecific EGFR–MET antibody with Fc-mediated immune effector activity, and the control regimen is standard pembrolizumab + platinum (carboplatin/cisplatin) + 5-FU.

ClinicalTrials.gov ID: NCT07276399

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: This clinical trial evaluates the safety and efficacy of the investigational drug NEO212, a novel conjugate of temozolomide and perillyl alcohol with enhanced brain penetration, in adults with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, or uncontrolled brain metastases from select solid tumors, including combinations with standard treatments like pembrolizumab or ipilimumab.

ClinicalTrials.gov ID: NCT06047379

Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring KRAS G12C mutations (including pretreated NSCLC and other solid tumors), who receive a combination of the investigational KRAS G12C inhibitors RMC-6291 and RMC-6236. Both agents specifically inhibit KRAS G12C mutant protein to suppress tumor growth, and eligibility includes both KRAS G12C inhibitor–naïve and previously treated patients, excluding those with primary CNS tumors or active brain metastases.

ClinicalTrials.gov ID: NCT06128551